Nasus Pharma Ltd Dossier
Qualitative Analysis
Business overview
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company incorporated in Israel in 2019 and headquartered in Tel Aviv. The company is focused on developing innovative, powder-based intranasal (PBI) therapies to treat acute and life-threatening emergency medical conditions. Leveraging its proprietary Nasax® platform, Nasus Pharma utilizes uniform spherical powder particles to optimize drug dispersion and rapid absorption through the nasal cavity's rich vascular network. This technology aims to provide needle-free, fast-acting, and easy-to-use alternatives to traditional injectable emergency treatments.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead product candidate, NS002 (an intranasal powder epinephrine spray), through clinical development as a needle-free alternative to epinephrine autoinjectors for anaphylaxis.
Expected impact: Establish clinical comparability to EpiPen to support a 505(b)(2) NDA submission.
Leveraging the proprietary powder-based intranasal (PBI) Nasax platform to develop additional candidates, including NS003 for chemotherapy-induced nausea, NS004 for metabolic disorders, and NS005 for cardiovascular disease.
Expected impact: Diversify the clinical pipeline and demonstrate the versatility of the PBI platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Nasus Pharma with access to Aptar's commercially proven Unit Dose System technology, manufacturing infrastructure, and supply chain capabilities to support clinical trials and regulatory submissions for NS002.
Terms: Specific financial terms were not disclosed in the public announcement.